Agilis Biotherapeutics Participates in Piper Jaffray GenomeRx Symposium

Dr. Mark Pykett, President and CEO, to present in panel session entitled “Thinking Smart About CNS Targeting Gene Therapy”

Cambridge, MA, May 17, 2016--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Agilis is participating in the Piper Jaffray GenomeRx Symposium being held in New York City, May 17 and 18, 2016. Dr. Mark Pykett, President and Chief Executive Officer of Agilis, will participate on the panel entitled “Thinking Smart About CNS Targeting Gene Therapy” held on Tuesday May 17 at 11:20am EST. The symposium brings together top executives and luminaries in gene therapy to discuss the latest breakthroughs and challenges.

“This pace-setting conference invites key leaders from private and public companies to discuss novel genetic treatments for devastating CNS disorders that have few, if any, treatment options,” said Dr. Pykett. “Significant advancements in the number and type of technologies in development to treat these devastating disorders have positioned the field for important advances in this exciting field of innovative genetic medicines. Agilis is pleased to be invited to participate in this unique conference discussion. Ongoing progress with our gene therapy programs, including encouraging clinical data and long-term follow-up from our AADC Deficiency program, as well as building momentum in our programs for Angelman syndrome and Friedreich’s ataxia as they proceed toward their INDs, provides evidence for the potential of this exciting treatment approach for rare disorders of the central nervous system.”

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative gene therapies designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company’s technology is aimed at the precise targeting
and restoration of a lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis’ rare disease programs are focused on gene therapy for AADC Deficiency, Friedreich’s ataxia, Angelman syndrome, and Fragile X syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information, contact:

Agilis Biotherapeutics

Dr. Jodi Cook
Vice President, Operations & Strategic Alliances
Email: jcook@agilisbio.com
Phone: 510-673-7809